Nilotinib

• CAT Number: A000374
• CAS Number: 641571-10-0
• Molecular Formula: C₂₈H₂₂F₃N₇O
• Molecular Weight: 529.52
• Purity: ≥95%
• Target: Autophagy
• Solubility: >26.5mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
• InChI: InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
• InChIKey: HHZIURLSWUIHRB-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

Nilotinib（Cat No.:A000374）is a selective tyrosine kinase inhibitor that primarily targets BCR-ABL, the fusion protein driving chronic myeloid leukemia (CML). It is used for the treatment of CML in patients who are resistant or intolerant to prior therapies like imatinib. Nilotinib binds to the inactive form of the BCR-ABL protein, blocking its ability to trigger cancer cell proliferation. It has demonstrated efficacy in managing CML, offering a more potent and selective approach with fewer off-target effects. Nilotinib’s improved safety profile and effectiveness make it a critical treatment option for CML.